Sponsor Pipeline

Nanjing Immunophage Biotech Co., Ltd Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
4
Recruiting
2
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-11 NCT07679113
IPG1094 Phase I Study for China Healthy Participants		 Recruitment opened
Active Trials by Phase
Phase 2
1
Phase 1/2
3
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07535489 Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis… Moderately to Severely Active Ulcerative Colitis (UC) Not Yet Recruiting
Phase 1/2
NCT06212076 Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients Solid Tumor Recruiting
NCT06717815 Phase IIa Study for IPG11406 in Patients With Lupus Nephritis Lupus Nephritis Recruiting
NCT07508761 IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors Advanced Solid Tumor Recruiting
Phase 1
NCT07679113 IPG1094 Phase I Study for China Healthy Participants Healthy Volunteers Recruiting
Disease Areas
Lupus (SLE) (1) Ulcerative Colitis (1)
Get alerts when Nanjing Immunophage Biotech Co., Ltd's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free